Chen SC, Ma DH, Zhong JJ. Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report. World J Clin Cases 2023; 11(27): 6579-6586 [PMID: 37900244 DOI: 10.12998/wjcc.v11.i27.6579]
Corresponding Author of This Article
Jia-Jian Zhong, MM, Surgeon, Hepatobiliary and Pancreatic Surgery, Huazhong University of Science and Technology Union Shenzhen Hospital, No. 89 Taoyuan Road, Nanshan District, Shenzhen 518052, Guangdong Province, China. jjzhong11@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 26, 2023; 11(27): 6579-6586 Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6579
Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
Si-Cong Chen, Dong-Heng Ma, Jia-Jian Zhong
Si-Cong Chen, Dong-Heng Ma, Jia-Jian Zhong, Hepatobiliary and Pancreatic Surgery, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518052, Guangdong Province, China
Author contributions: Zhong JJ contributed to manuscript writing and editing; Ma DH contributed to data collection; Chen SC contributed to conceptualization and supervision; All authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jia-Jian Zhong, MM, Surgeon, Hepatobiliary and Pancreatic Surgery, Huazhong University of Science and Technology Union Shenzhen Hospital, No. 89 Taoyuan Road, Nanshan District, Shenzhen 518052, Guangdong Province, China. jjzhong11@163.com
Received: June 13, 2023 Peer-review started: June 13, 2023 First decision: August 8, 2023 Revised: August 17, 2023 Accepted: August 23, 2023 Article in press: August 23, 2023 Published online: September 26, 2023
Abstract
BACKGROUND
Toripalimab and anlotinib have shown good response in esophageal cancer, with high objective response rate and progression free survival. Thus, they have been approved as second-line or above-line therapy for advanced or unresectable esophageal carcinoma. Combination of these two drugs may have synergistic effects, but evidence of which is lacking.
CASE SUMMARY
Here, we report on a 73-year-old male, newly diagnosed with advanced esophageal squamous cell carcinoma (ESCC), who received a combination of toripalimab and anlotinib. Complete response was achieved after treatment for 3 mo and remission was maintained up to 14 mo.
CONCLUSION
The combination therapy of toripalimab and anlotinib is a promising treatment for unresectable ESCC and related clinical trials are warranted.
Core Tip: Toripalimab and anlotinib have emerged as second-line or above-line treatment options for advanced esophageal cancer. However, their objective remission rates and progression-free survival are low when used alone. We report a case of complete response after combination therapy of toripalimab and anlotinib in a patient newly diagnosed with advanced esophageal squamous cell carcinoma. The patient was in remission for 14 mo. Hence, toripalimab combined with anlotinib may be a new and effective treatment for advanced unresectable esophageal squamous cell cancer.
